Drug development is a long and costly process. On the other hand, while AI platforms may rapidly identify compounds that work on cells in a Petri dish or in animal models, the success of these ...

Thalidomide, a drug once used to alleviate morning sickness in pregnant women, exhibits distinct properties due to its ...

Drug Development Is Slowing Down After Cuts at the FDA. Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials. By . Jared S. Hopkins.

Drug Development Is Slowing Down After Cuts at the FDA. Story by Jared S. Hopkins • 1mo. Biotech companies developing drugs for hard-to-treat diseases and other ailments are being forced to push ...

Of course, Novo Nordisk is a major player in the obesity drug development space with its drug Wegovy. However, it has faced some stiff competition from Eli Lilly with Zepbound (tirzepatide).

Artificial Intelligence could help accelerate drug development timeline, expert says . by Jade Lawson. Wed, May 14th 2025 at 2:34 PM. 3. VIEW ALL PHOTOS.

Consider lisinopril, approved for the treatment of hypertension in 1988, with subsequent development through the GISSI-3 trial (1994) resulting in an indication for acute myocardial infarction ...

Few truly innovative drugs for central nervous system (CNS) disorders have been approved in recent years, suggesting that there is a need for strategies to improve the productivity of research and ...

The impact of AI on drug development and compliance is already making waves, and it’s not slowing down. In fact, pharma companies that don’t embrace AI will struggle to remain competitive and ...

But regulation of drug development begins long before the approval deadline, and uncertainty and delay could arise at many points along the way. Related 50 new drugs received FDA approval in 2024 ...

The new approach aims to improve drug safety, reduce development time, and cut costs. It also aligns with growing scientific and public support for more human-relevant testing strategies.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. CNN values your feedback 1.